Skip to contentO
Oramed Pharmaceuticals Inc.
O
ORMPOramed Pharmaceuticals Inc. Q2 2023 · 10-Q
Revenue$674.00K$674.00K±0.0% vs Q2 2022 Net Income-$1.19M-$1.19MN/M vs Q2 2022 EPS Diluted-$0.03-$0.03N/M vs Q2 2022 Operating Income-$3,791,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Oramed Pharmaceuticals Inc. · CIK 1176309 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$2,654,000N/M Margins · derivedOperating margin-562.5%+1131.5 pt vs Q2 2022
Net margin-177.2%+1385.6 pt vs Q2 2022
ended Jun 30, 2023 · filed Aug 10, 2023 · 41 d after period end